PROCEPT BioRobotics (PRCT) Cash from Operations (2020 - 2026)

PROCEPT BioRobotics (PRCT) has reported Cash from Operations for 7 consecutive years, with -$19.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash from Operations fell 27.97% year-over-year to -$19.3 million in Q2 2026; TTM through Jun 2026 was -$74.3 million, a 10.66% increase from a year earlier, with the FY2025 full-year figure at -$49.0 million, up 50.63% from the prior year.
• Cash from Operations was -$19.3 million for Q2 2026 at PROCEPT BioRobotics, up from -$38.1 million in the prior quarter.
• Over five years, Cash from Operations peaked at -$6.6 million in Q3 2025 and troughed at -$38.1 million in Q1 2026.
• A 5-year average of -$21.9 million and a median of -$19.1 million in 2023 frame the typical range for Cash from Operations.
• Across the five-year window, Cash from Operations surged 68.12% in 2025 and slumped 124.54% in 2026, its largest moves.
• Over 5 years, Cash from Operations stood at -$25.2 million in 2022, then rose by 1.51% to -$24.8 million in 2023, then plunged by 30.65% to -$32.4 million in 2024, then surged by 68.12% to -$10.3 million in 2025, then tumbled by 86.41% to -$19.3 million in 2026.
• The last three Cash from Operations figures came in at -$19.3 million (Q2 2026), -$38.1 million (Q1 2026), and -$10.3 million (Q4 2025), per Business Quant data.